Conservative treatment of phimosis with fluticasone proprionate 0.05%: a clinical study in 1185 boys.
OBJECTIVE
Circumcision has been the traditional method of choice in the treatment of boys with phimosis. Recently, several published studies worldwide have focused their interest on more conservative approaches in management of this condition. These studies advocate the use of topical steroids in the phimotic foreskin. We aimed to investigate the efficacy and safety of a medium potency corticosteroid in boys with different types of prepuce retractabilty.


METHODS
A prospective study was performed involving boys referred to our hospital for possible phimosis between January 2004 and February 2008. All were treated initially with fluticasone proprionate 0.05% for a period of 4-8 weeks. Patients were reassessed after 6 months of follow up.


RESULTS
A total of 1185 boys with a diagnosis of phimosis were treated with fluticasone proprionate 0.05%. Successful results were achieved in 1079 (91.1%) patients including boys with mild balanitis xerotica obliterans. No side effects were noticed.


CONCLUSIONS
Our results show that fluticasone proprionate 0.05%, a mild potent corticosteroid, is effective and safe in the treatment of boys with different types of phimosis.
Zavras
Nick
N
Department of Paediatric Surgery, Penteli General Children's Hospital, 8 Hippocratous Str, 15236 P. Penteli, Athens, Greece. nikzav2000@yahoo.com
Christianakis
Efstratios
E
Mpourikas
Demetrios
D
Ereikat
Khalil
K
D000287:Administration, Topical; D000293:Adolescent; D000730:Androstadienes / Q000008:administration & dosage*; D052798:Balanitis Xerotica Obliterans / Q000188:drug therapy / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000008:administration & dosage*; D000068298:Fluticasone; D005500:Follow-Up Studies; D052816:Foreskin / Q000187:drug effects / Q000473:pathology; D006801:Humans; D008297:Male; D010688:Phimosis / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D016896:Treatment Outcome
D000730:Androstadienes; D003879:Dermatologic Agents; D000068298:Fluticasone